Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Life For AstraZeneca’s SLE Treatment As Second Study Succeeds

Executive Summary

The second Phase III TULIP trial for AstraZeneca’s anifrolumab has succeeded where the first failed by hitting a new primary endpoint in systemic lupus erythematosus.

You may also be interested in...



Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments. 

Real Hope For Lupus As AZ's Anifrolumab Impresses In Phase II

A Phase II trial of AstraZeneca's investigational monoclonal antibody, anifrolumab, in patients with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and secondary endpoints. The data were presented at the American College of Rheumatology 2015 Scientific Meeting in San Francisco this week.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel